Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureA review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes.Pursuit of a perfect insulin.How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.Glargine and degludec: Solution behaviour of higher dose synthetic insulins.In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.Characterisation of insulin analogues therapeutically available to patients.
P2860
Q22241148-B78C0DD2-8469-48F1-AD5F-F92E1BCD80DDQ30978373-78D8C694-6F96-4754-925B-D7DFD3517BF6Q36554243-C8F8C017-A4D2-42AC-9EEC-707A2D47BF3BQ38620136-A8291D8A-B75A-4953-840B-8B8AC291A8C9Q38778988-636D0689-ED9A-4EED-969A-408C946C9F24Q39023191-86163316-84F6-4D58-9C48-52CB4A2E50F2Q41260941-EC1B8D61-88D6-4BBB-8FC1-39FE5CFC872BQ42491076-3EDA4612-36F4-4507-A6F1-1156E3C44D6CQ46001828-231C5E08-2C68-46A0-A0D2-B699D717787BQ46082135-A3662AA6-9580-4159-A58A-20BF05A8C7E5Q51410348-30F932E3-1714-4B87-BA8D-CE87509EDB73Q52337945-556B1775-F36E-4E0E-A510-98D0447FD27F
P2860
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
description
2014 nî lūn-bûn
@nan
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@en
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@nl
type
label
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@en
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@nl
prefLabel
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@en
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@nl
P2093
P2860
P356
P1476
Contrasting weight changes wit ...... emic control in T1DM and T2DM.
@en
P2093
J Rosenstock
M J Prince
R M Bergenstal
S J Jacober
P2860
P304
P356
10.1111/DOM.12223
P577
2014-04-01T00:00:00Z